Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors
减轻儿童癌症幸存者的长期治疗相关发病率
基本信息
- 批准号:9976463
- 负责人:
- 金额:$ 81.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AgeAlabamaAmericanAmerican Society of Clinical OncologyAnthracyclineAwardCancer PatientCancer SurvivorshipChargeChronicClinical Trials Cooperative GroupCollaborationsCoupledDevelopmentDoseEpidemiologyFundingFutureGeneticGenetic Predisposition to DiseaseGoalsHealthHeart NeoplasmsIncidenceInfrastructureInstitutesInterventionLifeMalignant Childhood NeoplasmMalignant NeoplasmsModelingMolecularMolecular BiologyMorbidity - disease rateMyocardial dysfunctionNeoplasmsNewly DiagnosedOncologyOutcomeOutcomes ResearchPathogenesisPatientsPediatric OncologyPediatric Oncology GroupPeer ReviewPharmacogenomicsPhysiciansPopulationPremature MortalityPreventionPublicationsRadiationResearchResearch PersonnelRiskRoleShapesSocietiesTherapeuticTherapeutic AgentsUniversitiesanticancer researchchildhood cancer survivorclinical investigationcohortexperiencegenetic signaturehigh riskimprovedindexinginter-individual variationinterpatient variabilityleukemia/lymphomamembernovelpersonalized managementresponserisk prediction modelsurvivorshiptreatment risk
项目摘要
Cancer Relevance and Scientific Rationale: Childhood cancer survivors are at a life-long risk of chronic health
conditions; by age 50, the cumulative incidence of life-threatening/fatal chronic health conditions is 53%. The
two leading causes of premature mortality in childhood cancer survivors are radiation-related subsequent
neoplasms (SNs) and anthracycline-related cardiac dysfunction (CD). Radiation and anthracyclines are both
used in >60% of children with cancer, and there are no plans in the foreseeable future to eliminate these agents.
Although there is a dose-response relation between radiation and SN and between anthracyclines and CD
(regardless of the underlying primary cancer), there is significant inter-patient variability in the risk, suggesting
the moderating role of genetic predisposition. The high burden of morbidity coupled with the inter-individual
variability in risk, suggests a need and an opportunity to identify patients at highest risk for treatment-related
morbidity, such that targeted interventions can be instituted. Broad Plan: This application harnesses and merges
novel concepts from the field of molecular biology, pharmacogenomics and cancer survivorship to identify cancer
patients by their personal risk of SN or CD. This award also attempts to understand the molecular pathogenesis
of these complications to inform future development of targeted prevention/therapeutic strategies. The necessary
infrastructure for the proposed research, including banked, annotated biospecimens (n=13,450) and pre-existing
collaborations with the necessary expertise will be leveraged in this application. The goals are to: i) develop a
risk prediction model for radiation-related SN and anthracycline-related CD in childhood cancer survivors; ii)
replicate the optimized model in an independent cohort of childhood cancer survivors; iii) apply the optimized
model to newly-diagnosed children with cancer to predict the risk of incident SN/CD; iv) determine the functional
relevance of the genetic signatures. Qualifications: I am the founding Director of the Institute for Cancer
Outcomes and Survivorship at the University of Alabama at Birmingham. I have over 20y of experience
conducting cancer outcomes research that bridges the fields of oncology, epidemiology and genetics. Since
2000, I have been charged with shaping the pediatric oncology survivorship research agenda within the
Children's Oncology Group – an NCI-supported clinical trials group, devoted exclusively to pediatric cancer
research across 220 centers. I am currently serving as chair-elect for the ASCO survivorship committee. I am a
Leukemia Lymphoma Scholar, a recipient of the Frank H Oski award, and am an elected member of the American
Society of Clinical Investigation, and the Association for American Physicians. I have been continuously funded
by NCI since 2000. With over 235 peer-reviewed publications and 15,220 citations (9,300 since 2012), my
Google Scholar H-INDEX is 66 (54 since 2012) and my i10-index is 182 (167 since 2012). I am fully committed
to improving the long-term health of our childhood cancer survivors, and I strongly believe that findings from this
application will accelerate the pace to reduce the burden of morbidity in this population.
癌症相关性和科学依据:儿童癌症幸存者面临终身慢性健康风险
到50岁时,危及生命/致命的慢性健康状况的累积发病率为53%。的
儿童癌症幸存者过早死亡的两个主要原因是与辐射有关的随后死亡。
肿瘤(SN)和蒽环类药物相关的心功能障碍(CD)。辐射和蒽环类药物
在>60%的癌症儿童中使用,并且在可预见的未来没有计划消除这些药物。
尽管辐射与SN以及蒽环类药物与CD之间存在剂量-反应关系
(不考虑潜在的原发性癌症),风险存在显著的患者间差异,表明
遗传倾向的调节作用。高发病率负担加上个体间
风险的可变性,表明需要和机会来识别治疗相关风险最高的患者
发病率,这样就可以采取有针对性的干预措施。Broad Plan:此应用程序利用和合并
从分子生物学、药物基因组学和癌症存活率领域来识别癌症的新概念
患者的SN或CD个人风险。该奖项还试图了解分子发病机制
这些并发症,为今后制定有针对性的预防/治疗策略提供信息。必要的
拟议研究的基础设施,包括库存、注释生物标本(n= 13,450)和预先存在的
在这一应用中将利用与必要专门知识的协作。目标是:(一)制定一个
儿童癌症幸存者中辐射相关SN和蒽环类药物相关CD的风险预测模型; ii)
在儿童癌症幸存者的独立队列中复制优化的模型; iii)应用优化的模型,
模型,以预测事件SN/CD的风险; iv)确定功能性
基因特征的相关性资格:我是癌症研究所的创始主任
结果和生存在伯明翰的亚拉巴马大学。我有20多年的经验
开展癌症结果研究,将肿瘤学、流行病学和遗传学领域联系起来。以来
2000年,我被任命为制定儿科肿瘤生存研究议程,
儿童肿瘤学小组-一个由美国国家癌症研究所支持的临床试验小组,专门致力于儿科癌症
在220个中心进行研究。我目前担任ASCO幸存者委员会的当选主席。我是一个
白血病淋巴瘤学者,弗兰克H奥斯基奖的获得者,是美国
临床研究学会和美国医师协会。我一直得到资助
自2000年以来,NCI超过235篇同行评议的出版物和15,220次引用(自2012年以来有9,300次),我的
Google Scholar H-Index为66(自2012年以来为54),我的i10指数为182(自2012年以来为167)。我完全致力
改善我们儿童癌症幸存者的长期健康,我坚信,
这一应用将加快步伐,减轻这一人群的发病负担。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SMITA BHATIA其他文献
SMITA BHATIA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SMITA BHATIA', 18)}}的其他基金
Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors
减轻儿童癌症幸存者的长期治疗相关发病率
- 批准号:
9754794 - 财政年份:2018
- 资助金额:
$ 81.96万 - 项目类别:
Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors
减轻儿童癌症幸存者的长期治疗相关发病率
- 批准号:
10468239 - 财政年份:2018
- 资助金额:
$ 81.96万 - 项目类别:
Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors
减轻儿童癌症幸存者的长期治疗相关发病率
- 批准号:
10682635 - 财政年份:2018
- 资助金额:
$ 81.96万 - 项目类别:
Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors
减轻儿童癌症幸存者的长期治疗相关发病率
- 批准号:
10246837 - 财政年份:2018
- 资助金额:
$ 81.96万 - 项目类别:
Comprehensive Approach to Improve Medicine Adherence in Pediatric Leukmia
提高小儿白血病药物依从性的综合方法
- 批准号:
9390033 - 财政年份:2014
- 资助金额:
$ 81.96万 - 项目类别:
Comprehensive Approach to Improve Medicine Adherence in Pediatric Leukemia
提高小儿白血病用药依从性的综合方法
- 批准号:
8626018 - 财政年份:2014
- 资助金额:
$ 81.96万 - 项目类别:
Comprehensive Approach to Improve Medicine Adherence in Pediatric Leukmia
提高小儿白血病药物依从性的综合方法
- 批准号:
8987413 - 财政年份:2014
- 资助金额:
$ 81.96万 - 项目类别:
相似海外基金
Alabama Agricultural and Mechanical University ALSAMP Bridge to the Doctorate: Navigating BD Scholars’ Successful Transition to STEM Graduate Programs
阿拉巴马农业机械大学 ALSAMP 通往博士学位的桥梁:引导 BD 学者成功过渡到 STEM 研究生项目
- 批准号:
2404955 - 财政年份:2024
- 资助金额:
$ 81.96万 - 项目类别:
Standard Grant
Conference: Second Joint Alabama--Florida Conference on Differential Equations, Dynamical Systems and Applications
会议:第二届阿拉巴马州-佛罗里达州微分方程、动力系统和应用联合会议
- 批准号:
2342407 - 财政年份:2024
- 资助金额:
$ 81.96万 - 项目类别:
Standard Grant
IUCRC Planning Grant The University of Alabama: Center to Accelerate Recipe Development for Additive Manufacturing of Metals (CARDAMOM)
IUCRC 规划拨款阿拉巴马大学:加速金属增材制造配方开发中心 (CARDAMOM)
- 批准号:
2333363 - 财政年份:2024
- 资助金额:
$ 81.96万 - 项目类别:
Standard Grant
RAPID: DRL AI: A Career-Driven AI Educational Program in Smart Manufacturing for Underserved High-school Students in the Alabama Black Belt Region
RAPID:DRL AI:针对阿拉巴马州黑带地区服务不足的高中生的智能制造领域职业驱动型人工智能教育计划
- 批准号:
2338987 - 财政年份:2023
- 资助金额:
$ 81.96万 - 项目类别:
Standard Grant
Conference: Joint Alabama--Florida Conference on Differential Equations, Dynamical Systems and Applications
会议:阿拉巴马州-佛罗里达州微分方程、动力系统和应用联合会议
- 批准号:
2243027 - 财政年份:2023
- 资助金额:
$ 81.96万 - 项目类别:
Standard Grant
Conference: HBCU Excellence in Research and EPSCoR Regional Outreach Workshop at Alabama State University (HERO-ASU)
会议:阿拉巴马州立大学 HBCU 卓越研究和 EPSCoR 区域外展研讨会 (HERO-ASU)
- 批准号:
2404231 - 财政年份:2023
- 资助金额:
$ 81.96万 - 项目类别:
Standard Grant
RET Site: Engaging and Training Alabama STEM Teachers in Sensing Technologies
RET 网站:让阿拉巴马州 STEM 教师参与传感技术并对其进行培训
- 批准号:
2302144 - 财政年份:2023
- 资助金额:
$ 81.96万 - 项目类别:
Standard Grant
Equipment: Facilitating Optical X-Ray Techniques for Research and Organized Training at Alabama State University (FOXTROT-ASU)
设备: 阿拉巴马州立大学 (FOXTROT-ASU) 促进光学 X 射线技术研究和组织培训
- 批准号:
2324575 - 财政年份:2023
- 资助金额:
$ 81.96万 - 项目类别:
Standard Grant
NRT: Alabama Collaborative for Contemporary Education in Precision Timing (ACCEPT)
NRT:阿拉巴马州精密计时当代教育合作组织 (ACCEPT)
- 批准号:
2244074 - 财政年份:2023
- 资助金额:
$ 81.96万 - 项目类别:
Standard Grant
Louis Stokes Renewal STEM Pathways and Research Alliance: Alabama LSAMP
Louis Stokes 更新 STEM 途径和研究联盟:阿拉巴马州 LSAMP
- 批准号:
2308715 - 财政年份:2023
- 资助金额:
$ 81.96万 - 项目类别:
Continuing Grant